-
Phase I Open-Label, Dose Escalation Trial of BI 1831169 Monotherapy and in Combination with an Anti-PD-1 mAb in Patients with Advanced or Metastatic Solid Tumors. +
Phase I Open-Label, Dose Escalation Trial of BI 1831169 Monotherapy and in Combination with an Anti-PD-1 mAb in Patients with Advanced or Metastatic Solid Tumors.
Protocol No: 1456-0001
Age Group: Adult
Disease Sites: Eye and Orbit, Lip, Oral Cavity and Pharynx, Pancreas
NCT Id: NCT05155332
Phase: I
Principal Investigators: Tirrell Johnson, MD
Eligibility Document -
Attachment Id: 14732
File Name: UPDATED Subject Eligibility _Screening Checklist_1456-001_Part One (2).docx
URL:
Objective
To determine the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) for BI 1831169 both as monotherapy and in combination with an anti-PD-1 antibody and to assess the efficacy, safety and tolerability when given via intravenous and intratumoral routes.
-
A Phase 2B, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based hemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer COPERNICUS +
A Phase 2B, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based hemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer COPERNICUS
Protocol No: 61186372NSC2012
Age Group: Adult
Disease Sites: Lung
NCT Id: NCT06667076
Phase: II
Principal Investigators: Tirrell Johnson, MD
Eligibility Document -
Attachment Id: 8016
File Name: Subject Eligibility _Screening Checklist_61186372NSC2012.docx
URL:
Objective
To study how well amivantamab works when given with lazertinib or chemotherapy in patients with a certain type of non-small cell lung cancer that has an EGFR mutation.
-
A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations who are Ineligible for Intensive Chemotherapy +
A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations who are Ineligible for Intensive Chemotherapy
Protocol No: 75276617AML3001
Age Group: Adult
Disease Sites: Myeloid and Monocytic Leukemia
NCT Id: NCT06852222
Phase: III
Principal Investigators: Juan Varela MD, PhD
Eligibility Document -
Attachment Id: 16972
File Name: Subject Eligibility _Screening Checklist_JNJ75276617AML3001.docx
URL:
Objective
The primary objective is to determine whether the addition of bleximenib to VEN+AZA significantly improves the dual primary endpoints of CR rate or OS compared with VEN+AZA in participants with ND KMT2Ar or NPM1mAML who are ineligible for intensive chemotherapy
-
Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination with Chemoradiation Followed by Durvalumab for Locally Advanced and Unresectable Stage III Non-Small Cell Lung Cancer +
Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination with Chemoradiation Followed by Durvalumab for Locally Advanced and Unresectable Stage III Non-Small Cell Lung Cancer
Protocol No: 90301900NSC2001
Age Group: Adult
Disease Sites: Lung
NCT Id: NCT06667908
Phase: II
Principal Investigators: Tirrell Johnson, MD
Eligibility Document -
Attachment Id: 8069
File Name: Subject Eligibility _Screening Checklist _90301900NSC2001_ PART 1.docx
URL:
Objective
To determine whether JNJ-90301900 as a radioenhancer added to cCRT followed by cIT can improve objective response rate in participants with locally advanced and unresectable Stage IIIA and IIIB NSCLC
-
A Low-Interventional Study to Assess Physical Activity and Function in Adult Participants with Cachexia and Receiving or Will Be Receiving First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma +
A Low-Interventional Study to Assess Physical Activity and Function in Adult Participants with Cachexia and Receiving or Will Be Receiving First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
Protocol No: C3651032
Age Group: Adult
Disease Sites: Pancreas
NCT Id: NCT99999999
Phase: N/A
Principal Investigators: Jacobo Hincapie-Echeverri, MD
Objective
To estimate feasibility of deploying digital health technology (DHT) to quantitatively monitor physical activity in a non-clinical environment
-
A Phase 1 First-In-Human Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-617 Alone and in Combination with Pembrolizumab In Patients with Advanced Solid Tumors +
A Phase 1 First-In-Human Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-617 Alone and in Combination with Pembrolizumab In Patients with Advanced Solid Tumors
Protocol No: CLN-617-001
Age Group: Adult
Disease Sites: Eye and Orbit, Larynx, Lip, Oral Cavity and Pharynx, Melanoma, Skin
NCT Id: NCT06035744
Phase: I
Principal Investigators: Tirrell Johnson, MD
Eligibility Document -
Attachment Id: 14792
File Name: CLN-617-001 Screening Eligibility Checlist_V3.0 (BLANK).docx
URL:
Objective
This is a study testing a new drug, CLN-617, alone or with pembrolizumab to find the safest dose and check for side effects in people with advanced solid tumors.
-
A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer +
A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer
Protocol No: EIK1001-005
Age Group: Adult
Disease Sites: Lung
NCT Id: NCT06246110
Phase: II
Principal Investigators: Jennifer Tseng, MD
Eligibility Document -
Attachment Id: 7850
File Name: Subject Eligibility _Screening Checklist Version_EIK1001-005_V1_28Oct2024.docx
URL:
Objective
This study is testing a new drug, EIK1001, with pembrolizumab and chemotherapy in people with stage 4 non-small cell lung cancer to evaluate safety during treatment.
-
A Prospective, Open-label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination with Pembrolizumab Versus Docetaxel in Subjects with PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment with a PD1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) +
A Prospective, Open-label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination with Pembrolizumab Versus Docetaxel in Subjects with PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment with a PD1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06)
Protocol No: GCT1046-06
Age Group: Adult
Disease Sites: Lung
NCT Id: NCT06635824
Phase: III
Principal Investigators: Jennifer Tseng, MD
Eligibility Document -
Attachment Id: 12414
File Name: GCT1046-06_Subject Eligibility _Screening Checklist_PA1_v2.0_REVISION_FINAL.02Jun2025.docx
URL:
Objective
The purpose of this study is to see if the drug acasunlimab (GEN1046) combined with pembrolizumab works better than docetaxel for people with PD-L1 positive metastatic non-small cell lung cancer whose cancer has progressed after treatment with a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy. The amin goal is to find out whether the study treatment helps patients live longer.
-
A Phase II, Open-Label, Multicenter Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination with Gemcitabine Plus Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma +
A Phase II, Open-Label, Multicenter Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination with Gemcitabine Plus Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Protocol No: GO45434
Age Group: Adult
Disease Sites: Non-Hodgkin's Lymphoma
NCT Id: NCT06806033
Phase: II
Principal Investigators: Juan Varela MD, PhD
Eligibility Document -
Attachment Id: 14973
File Name: Subject Eligibility _Screening Checklist_GO45434.docx
URL:
Objective
This study will evaluate the optimization of the CRS profile for the Glofit-GemOx treatment regimen in patients with R/R DLBCL, using optimized regimen of steroids and a revised infusion and monitoring regimen to optimize the CRS profile of this treatment combination.
-
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) +
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Protocol No: ICONIC-A031702
Age Group: Adult
Disease Sites: Kidney, Other Endocrine System, Other Male Genital, Other Urinary, Prostate, Urinary Bladder
NCT Id: NCT03866382
Phase: II
Principal Investigators: Hatem Hassanein, MD
Objective
This study tests the combination of ipilimumab, nivolumab, and cabozantinib in patients with rare genitourinary cancers, measuring how many patients respond to the treatment based on tumor shrinkage or disappearance using RECIST 1.1 criteria.
-
An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants with Advanced Solid Tumors +
An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants with Advanced Solid Tumors
Protocol No: IDE397-001
Age Group: Adult
Disease Sites: Esophagus, Lung, Melanoma, Skin, Pancreas
NCT Id: NCT04794699
Phase: I
Principal Investigators: Tirrell Johnson, MD
Eligibility Document -
Attachment Id: 7934
File Name: Subject Eligibility Checklist Version 15MAR2024 final.docx
URL:
Objective
To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IDE397 alone and in combination with docetaxel or paclitaxel in adult participants with advanced solid tumors.
-
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-Positive Participants with Previously Treated Advanced Melanoma (TEBE-AM) +
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-Positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)
Protocol No: IMCGP100-203
Age Group: Adult
Disease Sites: Melanoma, Skin
NCT Id: NCT05549297
Phase: II/III
Principal Investigators: Tirrell Johnson, MD
Eligibility Document -
Attachment Id: 14448
File Name: Subject Eligibility _Screening Checklist Version 19JUL2024 (1).docx
URL:
Objective
To study if the drug tebentafusp, alone or with another therapy, can help people with advanced melanoma live longer and reduce cancer activity in their blood.
-
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease +
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Protocol No: INCA34176-357
Age Group: Both
Disease Sites: Other Hematopoietic
NCT Id: NCT06585774
Phase: III
Principal Investigators: Juan Varela MD, PhD
Objective
To compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe cGVHD.
-
A Phase 2, Multicenter, Open-Label Study of Lifileucel (Tumor-Infiltrating Lymphocytes [TIL]) in Participants with Previously Treated Advanced Endometrial Cancer +
A Phase 2, Multicenter, Open-Label Study of Lifileucel (Tumor-Infiltrating Lymphocytes [TIL]) in Participants with Previously Treated Advanced Endometrial Cancer
Protocol No: IOV-END-201
Age Group: Adult
Disease Sites: Other Female Genital
NCT Id: NCT06481592
Phase: II
Principal Investigators: Tirrell Johnson, MD
Objective
To evaluate the efficacy of lifileucel as measured by objective response rate per Response Evaluation Criteria in Solid Tumors in participants with dMMR or pMMR tumors based on the central laboratory assessment of MMR status
-
A Phase 1/2, Open-label Study of PD-1 Knockout Tumor-infiltrating Lymphocytes (IOV-4001) in Participants with Unresectable or Metastatic Melanoma or Stage III or IV Non-Small-Cell Lung Cancer +
A Phase 1/2, Open-label Study of PD-1 Knockout Tumor-infiltrating Lymphocytes (IOV-4001) in Participants with Unresectable or Metastatic Melanoma or Stage III or IV Non-Small-Cell Lung Cancer
Protocol No: IOV-GM1-201
Age Group: Adult
Disease Sites: Lung, Melanoma, Skin
NCT Id: NCT05361174
Phase: II/III
Principal Investigators: Juan Varela MD, PhD
Eligibility Document -
Attachment Id: 11553
File Name: Subject Eligibility _Baseline Checklist GM1.docx
URL:
Objective
This study is testing a new type of immune cell therapy called IOV-4001. It's being used in people with advanced melanoma or lung cancer to see if it is safe and whether it can help shrink tumors.
-
A Phase 3, Multicenter, Randomized, Open-Label, Parallel Group, Treatment Study to Assess the Efficacy and Safety of the Lifileucel (LN-144, Autologous Tumor Infiltrating Lymphocytes [TIL]) Regimen in Combination with Pembrolizumab Compared with Pembrolizumab Monotherapy in Participants with Untreated, Unresectable or Metastatic Melanoma +
A Phase 3, Multicenter, Randomized, Open-Label, Parallel Group, Treatment Study to Assess the Efficacy and Safety of the Lifileucel (LN-144, Autologous Tumor Infiltrating Lymphocytes [TIL]) Regimen in Combination with Pembrolizumab Compared with Pembrolizumab Monotherapy in Participants with Untreated, Unresectable or Metastatic Melanoma
Protocol No: IOV-MEL-301
Age Group: Adult
Disease Sites: Melanoma, Skin
NCT Id: NCT05727904
Phase: III
Principal Investigators: Juan Varela MD, PhD
Eligibility Document -
Attachment Id: 11633
File Name: Subject Eligibility _baseline Checklist IOV-MEL-301.docx
URL:
Objective
This study is looking at whether combining lifileucel with pembrolizumab helps patients more than pembrolizumab alone by measuring how many people respond to treatment and how long their cancer stays stable over five years.
-
A Phase 1B Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ATP150/ATP152, VSV-GP154 and Ezabenlimab (BI 754091) in Patients with KRAS G12D/G12V Mutated Pancreatic Ductal Adenocarcinoma (KISIMA-02) +
A Phase 1B Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ATP150/ATP152, VSV-GP154 and Ezabenlimab (BI 754091) in Patients with KRAS G12D/G12V Mutated Pancreatic Ductal Adenocarcinoma (KISIMA-02)
Protocol No: KISIMA-02
Age Group: Adult
Disease Sites: Pancreas
NCT Id: NCT05846516
Phase: I
Principal Investigators: Omar Kayaleh, MD
Eligibility Document -
Attachment Id: 5231
File Name: Subject Eligibility _Screening Checklist KISIMA 02.docx
URL:
Objective
This study is testing a combination of new cancer-fighting drugs to see if they are safe and might help people with a specific type of pancreatic cancer (KRAS-mutated) live longer or delay the return of their cancer.
-
A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE;FL-2) +
A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE;FL-2)
Protocol No: M22-003
Age Group: Adult
Disease Sites: Non-Hodgkin's Lymphoma
NCT Id: NCT06191744
Phase: III
Principal Investigators: Jose Sarriera, MD
Eligibility Document -
Attachment Id: 6409
File Name: Subject Eligibility _Screening Checklist M22-003_Version 2.0 dated 09Feb2024.docx
URL:
Objective
This study is testing if a new drug combination (epcoritamab with rituximab and lenalidomide) works better than standard chemotherapy for adults with previously untreated follicular lymphoma.
-
A Phase II, Open-Label, Multi-Cohort, Multicenter Study in Patients with Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis +
A Phase II, Open-Label, Multi-Cohort, Multicenter Study in Patients with Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis
Protocol No: ML44719
Age Group: Adult
Disease Sites: Liver
NCT Id: NCT06096779
Phase: II
Principal Investigators: Jacobo Hincapie-Echeverri, MD
Objective
This study is testing a new treatment in people with advanced liver cancer (hepatocellular carcinoma) who also have moderate liver damage. The goal is to see how safe the treatment is and to track any side effects.
-
A Phase 2 Randomized Study of Adjuvant Immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (KEYNOTE- 942). +
A Phase 2 Randomized Study of Adjuvant Immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (KEYNOTE- 942).
Protocol No: MODERNA-MRNA-4157-P201
Age Group: Adult
Disease Sites: Melanoma, Skin
NCT Id: NCT03897881
Phase: II
Principal Investigators: Tirrell Johnson, MD
Eligibility Document -
Attachment Id: 11672
File Name: Subject Eligibility _Screening p201.docx
URL:
Objective
This study is testing a personalized cancer vaccine (mRNA-4157) in combination with the immunotherapy drug pembrolizumab, compared to pembrolizumab alone. It is for people with high-risk melanoma who have had surgery The goal is to see which treatment better prevents the caner from coming back.
-
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination with Immune Checkpoint Blockade in Participants with Advanced Solid Tumors +
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination with Immune Checkpoint Blockade in Participants with Advanced Solid Tumors
Protocol No: MRNA-4359-P101
Age Group: Adult
Disease Sites: Lung, Melanoma, Skin
NCT Id: NCT05533697
Phase: I/II
Principal Investigators: Yuanbin Chen, MD
-
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease +
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Protocol No: NRG-GI008
Age Group: Adult
Disease Sites: Colon
NCT Id: NCT05174169
Phase: II/III
Principal Investigators: Omar Kayaleh, MD
Eligibility Document -
Attachment Id: 13913
File Name: NRG-GI008 CIRCULATE NA Subject Eligibility _Step 1-Study Entry Screening Checklist v4.0 08Jul2025.docx
URL:
Objective
This study is testing whether a blood test called ctDNA can help guide chemotherapy after surgery for stage II or III colon cancer. The goal is to see if using this test can safely reduce how many patients need chemotherapy or help give it only to who really need it, based on signs of cancer in the blood.
-
Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial +
Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Protocol No: NRG-LU007
Age Group: Adult
Disease Sites: Lung
NCT Id: NCT04402788
Phase: II/III
Principal Investigators: Jennifer Tseng, MD
Eligibility Document -
Attachment Id: 5906
File Name: LU007 DRAFT ELIGIBILITY.docx
URL:
Objective
This study is comparing two treatments to see which helps patients live longer and keeps their cancer from getting worse: atezolizumab with radiation versus atezolizumab alone.
-
A Phase 1/2, Open-Label Study to Investigate the Safety and Efficacy of Membrane Bound IL15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) in Participants with Advanced Solid Tumors +
A Phase 1/2, Open-Label Study to Investigate the Safety and Efficacy of Membrane Bound IL15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) in Participants with Advanced Solid Tumors
Protocol No: OBX115-23-01
Age Group: Adult
Disease Sites: Multiple Myeloma
NCT Id: NCT06060613
Phase: I/II
Principal Investigators: Tirrell Johnson, MD
Eligibility Document -
Attachment Id: 14052
File Name: OBX Subject Eligibility _Screening Checklist Version 19MAR2025 (1).docx
URL:
Objective
This study is testing a new kind of cell therapy called OBC-115 to see if it is safe and effective in people with advanced sold tumors.
-
Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors +
Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors
Protocol No: PRESERVE-003
Age Group: Adult
Disease Sites: Lung
NCT Id: NCT05671510
Phase: III
Principal Investigators: Tirrell Johnson, MD
Objective
This study is measuring how long patients live after starting treatment, with results tracked over three years. Survival time is calculated from when a patient joins the study until death from any cause.
-
A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants with Antigen-Positive Locally Advanced (Unresectable) or Metastatic Solid Tumors: PLEXI-T +
A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants with Antigen-Positive Locally Advanced (Unresectable) or Metastatic Solid Tumors: PLEXI-T
Protocol No: TSCAN-002
Age Group: Adult
Disease Sites: Anus, Cervix, Lip, Oral Cavity and Pharynx, Lung, Melanoma, Skin, Other Female Genital, Other Male Genital, Ovary
NCT Id: NCT05973487
Phase: I
Principal Investigators: Tirrell Johnson, MD
Eligibility Document -
Attachment Id: 10474
File Name: Subject Eligibility _TSCAN-002_Screening Checklist Version 28Mar2025.docx
URL:
Objective
To evaluate the safety and ideal dose of customized T cells (TCR-Ts) given alone or with T-Plex in people with advanced or inoperable antigen-positive solid tumors.
-
Screening Study to Determine HLA Type, HLA Loss of Heterozygosity Status and Tumor Antigen Expression in Participants with Locally Advanced (Unresectable) or Metastatic Solid Tumors. +
Screening Study to Determine HLA Type, HLA Loss of Heterozygosity Status and Tumor Antigen Expression in Participants with Locally Advanced (Unresectable) or Metastatic Solid Tumors.
Protocol No: TSCAN-003
Age Group: Adult
Disease Sites: Cervix, Eye and Orbit, Larynx, Lip, Oral Cavity and Pharynx, Lung, Melanoma, Skin, Ovary
NCT Id: NCT05812027
Phase: N/A
Principal Investigators: Tirrell Johnson, MD
Eligibility Document -
Attachment Id: 11474
File Name: Subject Eligibility _Screening Checklist_TSCAN-003_V3 23APR2025 (1).docx
URL:
Objective
This study collects tumor, saliva, or blood samples from patients with advanced or metastatic cancer to look for certain immune and genetic markers, the goal is to see if a person may qualify for a future Tscan clinical trial.
Navigate Your Health
Find a Cancer Physician
Find a Cancer Physician
Meet our doctors who specialize in the full range of cancer care. Our team of experts has experience in a variety of specialty areas. Together, we provide comprehensive evaluation, diagnosis and treatment options.
Learn More
Patient Portal
Patient Portal
If you are a patient at Orlando Health Cancer Institute, our free online patient portal provides an easy and secure way to manage your health information. Reach us from any location at a time that’s convenient for you.
Learn More
Virtual Visit
Virtual Visit
Need to talk with a doctor, but don’t want to leave your home? Try our virtual visit (telehealth) option to connect with a physician from your phone, tablet or computer.
Learn More
ER Wait Times
Tuesday, October 21, 2025 7:12 PM
|
|
Wait Time | |
|---|---|---|
| Orlando Health - Health Central Hospital | Directions | 5 min |
| Orlando Health Arnold Palmer Hospital for Children | Directions | 18 min |
| Orlando Health Bayfront Hospital Emergency Room | Directions | 129 min |
| Orlando Health Dr. P. Phillips Hospital | Directions | 3 min |
| Orlando Health Emergency Room - Blue Cedar | Directions | 3 min |
| Orlando Health Emergency Room - Crossroads | Directions | 2 min |
| Orlando Health Emergency Room - Four Corners | Directions | 1 min |
| Orlando Health Emergency Room - Lake Mary | Directions | 99 min |
| Orlando Health Emergency Room - Longwood | Directions | 9 min |
| Orlando Health Emergency Room - Osceola | Directions | 12 min |
| Orlando Health Emergency Room - Pinellas Park | Directions | 13 min |
| Orlando Health Emergency Room - Randal Park | Directions | 2 min |
| Orlando Health Emergency Room - Reunion Village | Directions | 35 min |
| Orlando Health Emergency Room - Waterford Lakes | Directions | 1 min |
| Orlando Health Horizon West Hospital | Directions | 4 min |
| Orlando Health Melbourne Hospital | Directions | 5 min |
| Orlando Health Orlando Regional Medical Center | Directions | 68 min |
| Orlando Health Sebastian River Hospital | Directions | 92 min |
| Orlando Health South Lake Hospital | Directions | 72 min |
| Orlando Health St. Cloud Hospital | Directions | 11 min |